Trial Profile
Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Shigella flexneri 2A vaccine (Primary)
- Indications Bacillary dysentery
- Focus Adverse reactions
- Sponsors GlycoVaxyn
- 21 Dec 2015 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
- 30 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
- 16 Mar 2015 Status changed from planning to recruiting as reported by Clinicaltrials.gov record.